XML 47 R35.htm IDEA: XBRL DOCUMENT
v3.19.1

Subsequent Events (Details) - Subsequent Event | May 07, 2019 antibody_and_vaccine protein | May 05, 2019 | Apr. 26, 2019
--- | --- | --- | ---
Serum | Collaborative Arrangement |  |  |
Subsequent Event [Line Items] |  |  |
Number of antibodies and vaccines for development and commercialization | antibody_and_vaccine | 12 |  |
Option to obtain exclusive commercial sub-license for number of proteins | protein | 12 |  |
Research funding, milestone payments and royalties, period | 15 years |  |
Novovet |  |  |
Subsequent Event [Line Items] |  |  |
Equity percentage |  |  | 20.00%
Alphazyme |  |  |
Subsequent Event [Line Items] |  |  |
Equity percentage |  | 7.50% |
Ownership interest consideration receivable upon extension of exclusivity period |  | 2.50% |
Alphazyme | Collaborative Arrangement |  |  |
Subsequent Event [Line Items] |  |  |
Exclusivity period |  | 18 months |
Option to extend exclusivity period |  | 12 months |

X
- Definition Collaborative Arrangement, Exclusivity Period + References No definition available. + Details
Name: | dyai_CollaborativeArrangementExclusivityPeriod
Namespace Prefix: | dyai_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Collaborative Arrangement, Number of Antibodies and Vaccines For Development And Commercialization + References No definition available. + Details
Name: | dyai_CollaborativeArrangementNumberofAntibodiesandVaccinesForDevelopmentAndCommercialization
Namespace Prefix: | dyai_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | instant

X
- Definition Collaborative Arrangement, Option To Extend Exclusivity Period + References No definition available. + Details
Name: | dyai_CollaborativeArrangementOptionToExtendExclusivityPeriod
Namespace Prefix: | dyai_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Collaborative Arrangement, Option to Obtain Exclusive Commercial Sub-License For Number of Proteins + References No definition available. + Details
Name: | dyai_CollaborativeArrangementOptiontoObtainExclusiveCommercialSubLicenseForNumberofProteins
Namespace Prefix: | dyai_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | instant

X
- Definition Collaborative Arrangement, Ownership Interest Consideration Receivable Upon Extension Of Exclusivity Period + References No definition available. + Details
Name: | dyai_CollaborativeArrangementOwnershipInterestConsiderationReceivableUponExtensionOfExclusivityPeriod
Namespace Prefix: | dyai_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | instant

X
- Definition Collaborative Arrangement, Research Funding, Milestone Payments And Royalties, Period + References No definition available. + Details
Name: | dyai_CollaborativeArrangementResearchFundingMilestonePaymentsAndRoyaltiesPeriod
Namespace Prefix: | dyai_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 323 -SubTopic 10 -Section 50 -Paragraph 3 -Subparagraph (a)(1) -URI http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571 + Details
Name: | us-gaap_EquityMethodInvestmentOwnershipPercentage
Namespace Prefix: | us-gaap_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | instant

X
- Definition Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event. + References No definition available. + Details
Name: | us-gaap_SubsequentEventLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Details
Name: | srt_CounterpartyNameAxis=dyai_SerumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | invest_InvestmentAxis=dyai_NovovetMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | invest_InvestmentAxis=dyai_AlphazymeMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |